This board is for fundamental and technical discussion about Amgen, AMGN.
Amgen Inc. (Amgen) is a global biotechnology company. It discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. In September 2006, Vectibix (panitumumab), Amgen's first oncology therapeutic, received the United States Food and Drug Administration approval and became commercially available in October 2006. The Company's principal products include Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim), EPOGEN (Epoetin alfa) and Enbrel (etanercept). On April 1, 2006, Amgen acquired Vectibix as part of its acquisition of Abgenix, Inc. On October 24, 2006, it acquired Avidia, Inc., which discovered and developed a class of human therapeutic known as Avimer proteins. In July 2007, it acquired Alantos and Ilypsa.
Share Price: $40.11 3/20/2008
52 Week High: $69.11
52 Week Low: $39.16
EPS: $2.82
P/E Ratio: 14.22
Outstanding Shares: 1.09 Billion
AMGEN INC
1 Amgen Center Dr
Thousand Oaks, CA 91320-1799
USA
Phone: 805-447-1000
Fax: 805-447-1010
http://www.amgen.com
Daily One-Year Charts
Weekly Five-Year Charts
